Scarica l'app Stockscreener
3.065
1.49%
0.045
Dopo l'orario di chiusura:
3.07
0.005
+0.16%
Precedente Chiudi:
$3.02
Aprire:
$3.46
Volume 24 ore:
75,721
Relative Volume:
7.43
Capitalizzazione di mercato:
$292.84M
Reddito:
$16.82M
Utile/perdita netta:
$-112.19M
Rapporto P/E:
-1.3817
EPS:
-2.2183
Flusso di cassa netto:
$-91.84M
1 W Prestazione:
+5.50%
1M Prestazione:
+8.69%
6M Prestazione:
+63.77%
1 anno Prestazione:
-16.26%
Intervallo 1D:
$2.90
$3.46
Intervallo di 1 settimana:
$2.88
$3.46
Portata 52W:
$1.53
$3.98
Inventiva Adr Stock (IVA) Company Profile
Confronta IVA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IVA
Inventiva Adr
|
3.065 | 292.84M | 16.82M | -112.19M | -91.84M | -2.2183 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Inventiva Adr Stock (IVA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-21 | Iniziato | TD Cowen | Buy |
| 2024-11-12 | Iniziato | UBS | Neutral |
| 2023-10-27 | Iniziato | Canaccord Genuity | Buy |
| 2023-05-31 | Iniziato | ROTH MKM | Buy |
| 2023-05-19 | Aggiornamento | Societe Generale | Sell → Buy |
| 2023-03-17 | Iniziato | Stifel | Buy |
| 2022-11-15 | Downgrade | Societe Generale | Buy → Sell |
| 2021-03-08 | Downgrade | Societe Generale | Buy → Sell |
| 2020-08-05 | Iniziato | ROTH Capital | Buy |
| 2020-08-04 | Iniziato | Guggenheim | Buy |
| 2020-08-04 | Iniziato | Stifel | Buy |
Mostra tutto
Inventiva Adr Borsa (IVA) Ultime notizie
Is Elicio Therapeutics, Inc. (ELTX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Inventiva achieves milestone with Phase 3 study enrollment, says H.C. Wainwright - TipRanks
Inventiva annonce la fin du recrutement de l’étude clinique de Phase 3 NATiV3 évaluant lanifibranor chez les patients atteints de MASH et de fibrose avancée - GlobeNewswire Inc.
Inventiva SA ADR Reports 2024 Financial Results and Strategic Updates - TipRanks
Top 10 Best Indian Companies In Smart Grids Solutions 2025 - Inventiva
Inventiva (IVA) Loses -17.66% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - MSN
Inventiva ADR (IVA) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
Stifel reiterates Buy rating on Inventiva stock, cites financing deal - Investing.com
Down -27.95% in 4 Weeks, Here's Why You Should You Buy the Dip in Inventiva (IVA) - Yahoo Finance
NOTA, No Votes and Unopposed Nominations: The Grey Areas of the Indian Election Process Explained - inventiva.co.in
symbol__ Stock Quote Price and Forecast - CNN
Supreme Court To Hear Plea Against Electoral Bonds From October 31 - Inventiva
Top 10 Best Handicraft Companies In USA 2023 - inventiva.co.in
Top 20 Best Hardware & Networking Company In India 2023 - Inventiva
Inventiva SaAdr Share Price Today (NASDAQ: IVA)Inventiva SaAdr Stock Price Live Quote - INDmoney
The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study - Yahoo Finance
The Daily Biotech Pulse: Moderna To Kickstart Phase 3 Study On July 27, Immutep Awarded Antibody Patent - Yahoo Finance
Inventiva Adr Azioni (IVA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):